Factor VIII deficiency is a bleeding disorder in which your blood lacks enough of a specific protein, called factor VIII, needed to form clots. It is the condition behind hemophilia A, the most common severe inherited bleeding disorder, affecting roughly 25 out of every 100,000 males born worldwide. Without adequate factor VIII, even minor injuries can lead to prolonged bleeding, and in severe cases, bleeding can start spontaneously inside joints and muscles.
How Factor VIII Works in Clotting
When you cut yourself, your body launches a chain reaction of proteins that ultimately builds a clot to stop the bleeding. Factor VIII plays a critical role in this chain. Once activated, it pairs with another protein called factor IX, and together they trigger a rapid series of reactions that produce a stable clot. Think of factor VIII as a catalyst that dramatically speeds up the process. Without it, the clotting cascade stalls, and bleeding continues far longer than it should.
Why It Happens: The Genetics
The gene responsible for producing factor VIII sits on the X chromosome. Because males have only one X chromosome (paired with a Y), a single defective copy of the gene is enough to cause the disorder. Females have two X chromosomes, so a normal copy on one can usually compensate for a faulty copy on the other. This is why hemophilia A overwhelmingly affects males, while females typically act as carriers.
If a mother carries the hemophilia gene and the father is unaffected, each son has a 50% chance of inheriting hemophilia, and each daughter has a 50% chance of becoming a carrier. In about a third of cases, the genetic mutation appears spontaneously with no family history at all.
Severity Levels
Factor VIII deficiency is classified by how much functional factor VIII circulates in the blood, measured as a percentage of normal activity:
- Mild: Factor VIII activity between 5% and 40% of normal. Bleeding problems usually show up only after surgery, dental work, or significant injury.
- Moderate: Factor VIII activity between 1% and 5%. Bleeding can occur after minor trauma and occasionally without an obvious trigger.
- Severe: Factor VIII activity below 1%. Spontaneous bleeding into joints and muscles is common, often beginning in early childhood.
About 9.5 out of every 100,000 males are born with the severe form. Severity tends to run consistently within families because the specific gene mutation dictates how much factor VIII the body can produce.
Signs and Symptoms
The hallmark of factor VIII deficiency is bleeding that is prolonged, excessive, or occurs without clear cause. In severe cases, the most characteristic problem is hemarthrosis, or bleeding into joints. The knees are the most frequently affected (about 45% of bleeds in untreated patients), followed by the elbows (30%) and ankles (15%). Shoulders and wrists account for a smaller share. In children receiving preventive treatment, the ankle has become the most common site of joint bleeding.
Beyond joints, people with factor VIII deficiency may experience deep muscle bleeds that cause swelling and pain, large bruises from minor bumps, prolonged bleeding after cuts or dental procedures, and nosebleeds that are hard to stop. More dangerous but less common events include bleeding inside the skull or in the space behind the abdominal organs. In severe hemophilia, a “target joint” can develop when the same joint bleeds four or more times within six months. About a third of people with severe hemophilia develop at least one target joint, compared to roughly 5% of those with the mild form.
How It Is Diagnosed
Diagnosis typically starts when a child bruises unusually easily or bleeds excessively after a minor procedure. A standard screening blood test called the activated partial thromboplastin time (aPTT) measures how long it takes blood to clot through the pathway that depends on factor VIII. In factor VIII deficiency, this time is prolonged. A follow-up test then measures factor VIII activity directly, confirming the diagnosis and establishing the severity level. Genetic testing can identify the specific mutation, which is especially useful for identifying female carriers or for prenatal testing.
Treatment With Factor Replacement
The cornerstone of treatment for decades has been replacing the missing factor VIII by infusing it into a vein. These concentrates come in two forms: plasma-derived products, manufactured from donated human blood, and recombinant products, made using genetically engineered cells without human blood components. Both are effective, and modern manufacturing processes include rigorous steps to eliminate the risk of transmitting infections.
Factor replacement can be given “on demand” to treat a bleed that has already started, or as prophylaxis, meaning regular infusions to keep factor VIII levels high enough to prevent spontaneous bleeding. Prophylaxis has transformed outcomes for children with severe hemophilia, significantly reducing joint damage. The main inconvenience is that standard factor VIII has a relatively short lifespan in the body, so prophylactic infusions are needed multiple times per week through an IV line.
Inhibitors: When Treatment Stops Working
One of the most serious complications of factor replacement is the development of inhibitors. These are antibodies the immune system produces against the infused factor VIII, neutralizing it before it can do its job. Inhibitors develop in roughly 30% of children with severe hemophilia A. A large study found a cumulative incidence of 32.4%, with about 22% of patients developing high levels of these antibodies. When inhibitors are present, standard factor VIII infusions become ineffective, and alternative strategies are needed.
Newer Treatment Options
A significant advance for people with factor VIII deficiency, particularly those with inhibitors, is emicizumab. This is an injectable medication that mimics what activated factor VIII does in the clotting cascade. It works by bridging activated factor IX and factor X, essentially standing in for the missing protein. Unlike factor VIII concentrates, emicizumab is given as a shot under the skin rather than into a vein, and it has a half-life of about 30 days. That means dosing can be as infrequent as once every four weeks, a dramatic improvement over the multiple weekly IV infusions that standard prophylaxis requires. It is now approved for people with hemophilia A regardless of whether they have inhibitors.
Gene therapy represents another leap forward. In 2023, the FDA approved the first gene therapy for severe hemophilia A in adults. It works by delivering a functional copy of the factor VIII gene into liver cells using a modified virus as a carrier. The goal is for the body to begin producing its own factor VIII, potentially reducing or eliminating the need for regular infusions. It is approved specifically for adults with severe disease who do not have pre-existing antibodies to the viral carrier, which would block the therapy from working.
Joint Health and Long-Term Outlook
Repeated bleeding into the same joint triggers a cycle of inflammation and damage that, over time, breaks down cartilage and leads to a form of arthritis called hemophilic arthropathy. This was once nearly inevitable for people with severe hemophilia, but early prophylaxis starting in childhood has dramatically reduced joint destruction. For those who do develop joint damage, management includes physical therapy to maintain range of motion and muscle strength, and in advanced cases, joint replacement surgery.
Research in animal models has also suggested that factor VIII deficiency may contribute to low-grade chronic inflammation in the liver, independent of any viral infections that historically affected people who received blood products. This is an area where long-term monitoring matters, particularly for older patients who were treated before modern screening methods existed.
Life expectancy for people with factor VIII deficiency has improved enormously over the past several decades. With access to prophylaxis, newer therapies like emicizumab, and now gene therapy, many people with hemophilia A live full, active lives. The condition requires ongoing management, but the trajectory of treatment options continues to shift the balance from managing complications to preventing them entirely.